Amgen Inc. Common Stock (AMGN)
NASDAQ
Closed
Oct 20, 2026
Day's Range
425.1152 wk Range
288.00Overview - AMGN - Amgen Inc. Common Stock
Key Statistics
Valuation
Enterprise Value
273.05B
P/E (Trailing)
‪26.39‬
P/E (Forward)
‪17.34‬
PEG Ratio
‪0.40‬
Price / Sales (TTM)
‪6.03‬
Price / Book
‪19.65‬
EV / EBITDA
‪15.81‬
Profitability
Gross Margin
‪72.04%‬
Profit Margin
‪22.95%‬
Operating Margin
‪35.54%‬
Return on Assets
‪8.66%‬
Return on Equity
‪91.47%‬
Ownership
Shares Outstanding
540.60M
Float
539.15M
Short % of Shares Outstanding
‪2.59%‬
Held by Insiders
‪0.22%‬
Held by Institutions
‪85.11%‬
Price stats
Beta
‪0.40‬
50-Day Avg
‪415.01‬
200-Day Avg
‪368.90‬
Dividends
Payout Ratio
‪60.87%‬
Frequency
Quarterly
Analyst Consensus
34 analysts
Average price target
‪$ 388.48‬Shariah Compliance
Report Date: Feb 16, 2025
Screened by Zoya using the AAOIFI methodology.
Market Cap - AMGN - Amgen Inc. Common Stock
Peers - AMGN - Amgen Inc. Common Stock
Peer Comparison
Compared with companies in Drug Manufacturers - General listed on NASDAQ.
- AMGNNASDAQAmgen Inc. Common Stock223.19BMarket Cap+28.82%52-week change25.64P/E (Trailing)‪22.95%‬Profit Margin
- AZNNASDAQAstraZeneca PLC American Depositary Shares256.53BMarket Cap-1.41%52-week change23.77P/E (Trailing)‪17.02%‬Profit Margin
- GILDNASDAQGilead Sciences, Inc.189.79BMarket Cap+18.94%52-week change17.87P/E (Trailing)‪-10.63%‬Profit Margin
- SNYNASDAQSanofi ADR95.22BMarket Cap-22.80%52-week change21.20P/E (Trailing)‪8.09%‬Profit Margin
- ROPNASDAQRoper Technologies Inc.37.85BMarket Cap-32.19%52-week change15.76P/E (Trailing)‪30.24%‬Profit Margin
- BIIBNASDAQBiogen Inc.33.89BMarket Cap+36.93%52-week change40.09P/E (Trailing)‪8.32%‬Profit Margin
- GRFSNASDAQGrifols S.A. ADR5.19BMarket Cap-25.26%52-week change9.92P/E (Trailing)‪6.09%‬Profit Margin
Profile Summary - AMGN - Amgen Inc. Common Stock
About
Amgen Inc. Common Stock represents ownership in Amgen Inc., a biotechnology company focused on discovering, developing, manufacturing, and marketing human therapeutics for serious diseases. The company’s portfolio spans therapies used in oncology, inflammation, cardiovascular conditions, osteoporosis, and rare…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Shariah compliance data provided by Zoya. Charting by TradingView.
Last updated:
